EyeGate Pharma develops ocular therapeutics and is advancing a pipeline using its proprietary EyeGate® II Delivery System, a non-invasive iontophoretic drug delivery platform. Its lead program, EGP-437, is a dexamethasone‑derived corticosteroid solution formulated to treat Dry Eye Syndrome (DES). The company raised an additional $5.9M as part of its Series D, bringing the Series D total to $28.5M to date. These funds will be used to continue development of EGP-437. The ALLUVION Phase III study of EGP-437 is fully enrolled and is awaiting last patient last visit, with top-line data expected by the end of Q1 2011. A prior Phase II study showed significant improvements in signs and symptoms of dry eye during and after Controlled Adverse Experiment exposure. EyeGate Pharmaceuticals is a Waltham, MA-based company developing ocular therapeutics and a proprietary non-invasive iontophoretic drug delivery system (EyeGate® II). The company is advancing EGP-437, a dexamethasone-derived corticosteroid solution, for the treatment of Dry Eye Syndrome (DES). According to EyeGate, EGP-437 significantly improved the signs and symptoms of DES in a Phase II clinical study. A pivotal study was expected to begin in the first half of 2010. EyeGate raised $22.6M in Series D financing, with $11M available immediately and $11.6M held in reserve. The new capital will support continued development of EGP-437 and the company’s pipeline using its EyeGate II delivery system.

Total raised

$29M

Funding rounds

2

Latest round

Series D

Latest activity

Jan 2011